Hover over the box to read a short bio of the interviewee.
Click on the box to read the full transcript of their interview.
Dr. David Peabody is a professor of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine. After studying the fundamental molecular characteristics of MS2 (a virus of E. coli), Dr. Peabody and his collaborator, Dr. Bryce Chackerian, have created a new technological platform to developed vaccines based on virus-like particles (VLPs) of MS2.
Myoung Chan Kim
My name is Myoung Chan Kim, currently a clinical professor at Inha University Hospital. I work at the Incheon International Airport Medical Center where I encounter many passengers who potentially test positive for COVID-19 every day. Before the corona outbreak, I worked as a doctor in South Korea, while establishing hospitals in Tanzania as an Official development assistance expert for KOICA.
Incheon, South Korea
Dr. Bryce Chackerian is a researcher in New Mexico. He is a Professor and Vice Chair of Molecular Genetics and Microbiology at the University of New Mexico. He received his BA at the University of California, Berkeley, and completed his PhD at the University of Washington, studying the immune selection of Simian Immunodeficiency Virus. Dr. Chackerian also trained at the National Cancer Institute. Dr. Chackerian’s lab mostly focuses on studying vaccine development as it relates to using virus particles as a platform for antigen display.
Dr. Lynora Saxinger is an Associate Professor of Medicine at University of Alberta and an Infectious Diseases specialist. Besides teaching and clinical practice, her interest lies in antimicrobial stewardship, an effort sought to improve both the prescription and use of antibiotics. Correspondingly, her recent work has centered around investigating appropriate use of antibiotics in minimizing the progression of antimicrobial resistance. In addition, Dr. Saxinger holds firm interest in knowledge translation and determining ways to communicate scientific findings to the public effectively.
I am one of a group of five doctors who take care of COVID-19 patients in the hospital. We have tried to limit exposure to these patients in our hospital by our providers, so we have a small group that takes care of all positive cases. I serve as a reference for other MDs regarding COVID-19 questions, specifically testing and treatment, and often take calls into the evening in that regard. I am also on a COVID-19 task force along with several infectious disease doctors, a pharmacist, a pathologist—responsible for coordinating testing—, and an intensivist, who help guide the hospital regarding COVID-19.
I'm a senior and an aspiring medical student at the Massachusetts Institute of Technology. Although I'm not a medical student yet, I have a background highly associated with medicine thanks to many internship experiences as well as with my family members who work in the medical field.